The results of clinical islet transplantation have remained poor when
compared with the consistent success of pancreas transplantation. Auto
immunity has usually been discounted as a cause of islet transplant fa
ilure, Previously, we demonstrated that pancreas transplants from the
diabetes resistant BB rat (BB-DR) function indefinitely in autoimmune
diabetic hosts, but islets from the same donor are vulnerable to recur
rent autoimmunity, Addition of 100 million pancreatic lymph node cells
(PLNC) to BE-DR islets restores resistance to autoimmunity and leads
to repletion of a T cell subset (RT6.1) in the recipients. Autoimmune
(BB-Ac) and streptozocin (BB-Sz) diabetic BE rats were recipients of W
istar Furth (WF) intraportal islet or islets plus PLNC transplants wit
h cyclosporine 5 mg/kg/day recipient treatment. One cohort of Brown No
rway (BN) islet transplants to BB-Ac with CsA was performed. At the te
rmination of the experiment, recipient peripheral blood lymphocytes (P
BL) were characterized by flow cytometry (FACS) for class I, CD4, CD8,
RT6.1, and RT6.2, a T cell maturation marker found in WF but not BE r
ats. All (14/14) WF and 75% (6/8) BN islet transplants to BB-Ac recipi
ents failed after a mean of 42 and 36 days, respectively, despite CsA
immunosuppression. WF islets were successful in 6/8 (75%) transplants
to BB-Sz recipients (P<0.001 vs, BB-Ac recipients), confirming that au
toimmunity is the major cause of islet failure in BB-Ac rats. Addition
of PLNC to WF islets increased the survival in BB-Ac to 82% (9/11) (P
<0.0001 vs. WF islets alone). Recipients of islet + PLNC express 19.7%
RT6.2 compared with 4.6% and 4.0% for WF islets alone in BB-Ac (P<0.0
1) and BB-Sz (P<0.01), respectively. Autoimmunity is an important fact
or leading to islet transplant failure in autoimmune diabetic BB rats,
Addition of donor PLNC prevent islet allograft failure and leads to r
ecipient chimerism for a donor T cell subset (RT6.2) associated with r
esistance to autoimmunity.